WisdomInterface
Marketing

Zero Candida Announces Launch of New Website

Zero candida

Company is in the Process of Being Listed on the TSX Venture Exchange (Canada) at a Proposed Valuation of 40 Million Canadian Dollars

VANCOUVER, BC, Aug. 26, 2024 /PRNewswire/ — Zero Candida (the “Company” or “ZC”), an Israeli FemTech medical device start-up, is pleased to announce the launch of a new digital website. The site offers technology that will showcase the Company’s story, provide investor updates, and share media. The digital site is now available: Zero Candida – Candida diagnostic and treatment device (zero-candida.com).

The company is in the process of applying to the TSX Venture Exchange in Canada to list its shares at a proposed valuation of 40 million Canadian dollars.

Zero-Candida’s technology is a game-changer that has the potential to change the treatment of women and FemTech industry in the world. The first of its kind technology using a controlled “Blue Light,” destroys the fungus at record speed and without side effects. The treatment is carried out by a tampon-like medical device which, according to medical experts, provides an optimal solution for removing the fungus altogether and preventing the recurrence of the disease.

Another significant advantage of the Zero Candida device is treatment without side effects, supporting growing demand from women to improve their health without the use of chemicals.

Eli Ben Haroosh, Founder & CEO: “Our new website showcases technology that will be a game changer in the field of women’s health in the world. The company is advancing in its research with the hope of involving hospitals and academic institutions around the world. Our website will be the link between important health care and our community of women worldwide.”

“Zero Candida has a potential to become a technological leader and use its ground-breaking technology to expand boundaries of non-chemical candida treatment,” added Ben Haroosh.

Summary of Transaction

Pursuant to the business combination agreement (the “Agreement”) between a Canadian reporting issuer (the “Reporting Issuer”) and the Company, the transaction is expected to be contemplated by a three-cornered amalgamation, where the Reporting Issuer’s wholly owned Israeli subsidiary incorporated solely for the purpose of the transaction, is expected to amalgamate with ZC. Each holder (each a ” ZC Shareholder”) of ZC Share, other than a ZC Shareholder who exercised Dissent Rights (as defined in the Israeli Companies Law) is expected to receive 8.6277 (eight and six thousand two hundred seventy seven ten-thousandths) shares in the capital of the Reporting Issuer (each a “Resulting Issuer Share”) in exchange for each ZC Share held by such ZC Shareholder, resulting in the Company issuing up to an aggregate of 12,223,232 Resulting Issuer’s Shares (which will represent approximately 85.94% of the issued and outstanding Resulting Issuer Shares, without taking into consideration any ZC share purchase warrants to be exercised immediately prior to completion of the Transaction, stock options or a concurrent financing). Additionally, the holders of stock options of ZC will be entitled to receive Resulting Issuer Shares, instead of ZC Shares, on the exercise of their options.

About Zero Candida:

ZC is a private FemTech technology company incorporated under the corporate laws of the State of Israel. ZC is developing an AI smart tampon-like device based on AI on a therapeutic light source with a selected wave-length and intensity that can treat the Candida fungus successfully with 99.999% efficacy as a POC (Proof of Concept). Vulvo-Vaginal Candidiasis (“VVC”) affects about 75% of women globally; each year 138 million women are affected world-wide and 492 million over their lifetime. Recurrent VVC (4 or more episodes per year) is increasingly documented to become drug resistant to existing treatments and constitutes up to 10% of the cases of VVC. Existing treatments are unable to overcome the high rate of recurrence, since the root cause of the condition is poorly understood and addressed.

ZC has signed pre-clinical agreements with hospitals in Israel and Europe and the company has successfully completed a safety trial for the use of a pre-clinical device in large animals (sheep) ZC continues the development of the final product for human use in preparation for a clinical trial that will take place in June 2025.

Zero Candida’s device will bring the field of gynecology into the 21st century with hybrid medicine and technology-based diagnostics. At the same time as developing the treatment procedure, Zero Candida is working on creating a technology to enable the hybrid medicine services to be provided by gynecologists to populations that until now received no treatment at all, including, among others, in the developing countries.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Forward-Looking Statements

This news release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, are forward-looking statements. The Company provides no assurance that forward-looking statements and information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements or information. Accordingly, readers should not place undue reliance on forward-looking statements or information. The Company does not undertake to update any forward-looking statements, other than as required by law. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by Zero Candida. Readers are cautioned not to place undue reliance on forward-looking statements.

Contact:
Eli Ben Haroosh, CEO & Founder
E: info@zero-candida.com
Website: www.Zero-Candida.com
Facebook: @Zero-candida

View original content: https://www.prnewswire.co.uk/news-releases/zero-candida-announces-launch-of-new-website-302230299.html

Subscribe for more insights



    By completing and submitting this form, you understand and agree to WisdomInterface processing your acquired contact information as described in our privacy policy.

    No spam, we promise. You can update your email preference or unsubscribe at any time and we'll never share your details without your permission.

    SUBSCRIBE
    Image Processing

    Who We Are

    Xcellent Insights is a futuristic market intelligence firm, headquartered in New York, US that focuses on providing strategic market insights. We offer a plethora of data-centric research reports and consulting services to help customers expand and explore their business strategies, obtain clarity about current business trends and future development, and attain substantial growth. Our portfolio of services includes syndicated and custom research reports driven by end-to-end market research and market intelligence studies.

    What We Do

    We strive to offer the best market research and consulting services to our customers that will benefit them in making informed business decisions. We provide an extensive list of market research titles falling under various industry categories such as consumer goods, food, and beverages, automotive, healthcare, and chemicals, covering latest and trending market insights. Through our services, we aim to connect an organization’s goal with lucrative outcomes globally.

      Subscribe for more insights



      By completing and submitting this form, you understand and agree to WisdomInterface processing your acquired contact information as described in our privacy policy.

      No spam, we promise. You can update your email preference or unsubscribe at any time and we'll never share your details without your permission.

        Subscribe for more insights



        By completing and submitting this form, you understand and agree to WisdomInterface processing your acquired contact information as described in our privacy policy.

        No spam, we promise. You can update your email preference or unsubscribe at any time and we'll never share your details without your permission.

          Baixe o recurso completo:












          Você reconhece que a Tenable, nossas afiliadas e terceiros (conforme aplicável) listados em nossa Política de Privacidade podem transferir seus dados pessoais para fora do país em que você reside para entregar comunicações de marketing a você, e os países para os quais seus dados pessoais podem ser transferidos podem não exigir o nível equivalente de proteção de seus dados pessoais.

            Descargar ahora:










            Número de empleados

            Usted reconoce que Tenable, nuestros afiliados y terceros (según corresponda) que figuran en nuestra Política de Privacidad pueden transferir sus datos personales fuera del país en el que reside, para enviarle comunicaciones de marketing y los países a los que se pueden transferir sus datos personales pueden no requerir el nivel equivalente de protección de sus datos personales.

              Download the Complete Resource:











              I would like to receive marketing communications from Tenable regarding its products and services.

              You may opt-out of receiving our emails at any time by following the opt-out instructions included in the footer of the emails delivered to you or by visiting Tenable's Subscription Center. You acknowledge that Tenable, our affiliates, and the third parties (as applicable) listed in our Privacy Policy may transfer your personal data outside of the European Economic Area ("EEA") in order to deliver marketing communications to you, and that countries outside of the EEA may not require the equivalent level of protection of your personal data. Tenable will only process your personal data as described in our Privacy Policy.

                Download the Complete Resource:











                I would like to receive marketing communications from Tenable regarding its products and services.

                You may opt-out of receiving our emails at any time by following the opt-out instructions included in the footer of the emails delivered to you or by visiting Tenable's Subscription Center. You acknowledge that Tenable, our affiliates, and the third parties (as applicable) listed in our Privacy Policy may transfer your personal data outside of the European Economic Area ("EEA") in order to deliver marketing communications to you, and that countries outside of the EEA may not require the equivalent level of protection of your personal data. Tenable will only process your personal data as described in our Privacy Policy.

                  Laden Sie die vollständige Ressource herunter:











                  Ich möchte Marketinginformationen von Tenable bezüglich deren Produkte und Dienstleistungen erhalten.

                  Sie haben jederzeit die Möglichkeit, sich aus dem Email-Verteiler löschen zu lassen. Folgen Sie dafür einfach der Opt-Out-Anleitung im Email-Footer oder besuchen sie Tenables Subscription Center. Sie stimmen zu, dass Tenable sowie die in unserer Privacy Policy aufgeführten Partner und Drittparteien (falls zutreffend) Ihre personenbezogenen Daten außerhalb der EU transferieren, um Ihnen Marketingkommunikationen zuzusenden, und dass Länder außerhalb der EU möglicherweise nicht den gleichen Level an Schutz für personenbezogene Daten vorschreiben. Tenable wird Ihre personenbezogenen Daten ausschließlich wie in unserer Privacy Policy beschrieben verarbeiten.

                    Téléchargez la ressource complète:











                    J'aimerai recevoir des communications de Tenable concernant ses produits et services.

                    Vous pouvez refuser de recevoir nos courriels à tout moment en suivant les instructions de désinscription incluses dans le pied de page de nos emails ou directement sur page d'abonnement de Tenable. Vous reconnaissez que Tenable, nos affiliés et les tiers (selon le cas) énumérés dans notre Politique de confidentialité peuvent transférer vos données personnelles en dehors de l'Espace économique européen (EEE) afin de vous fournir des communications, et que la réglementation des pays hors de l'EEE peut ne pas exiger le même niveau de protection de vos données personnelles. Tenable traitera vos données personnelles uniquement comme décrit dans notre politique de confidentialité.

                      Subscribe for more insights



                      By completing and submitting this form, you understand and agree to WisdomInterface processing your acquired contact information as described in our privacy policy.

                      No spam, we promise. You can update your email preference or unsubscribe at any time and we'll never share your details without your permission.